TrialMultiple sclerosis (Houndmills, Basingstoke, England)2022

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.

Ralf Gold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.